Template:Plasma levels and binding potential of flutamide and bicalutamide during first week
| Day | Total levels (ng/mL) | Free levels (ng/mL) | Ratios | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bicalutamide | Flutamidea | Bicalutamide | Flutamidea | Free | Binding potentialb | ||||||
| 1 | 901 | 940 | 36.0 | 66 | 0.55 | 2.18 | |||||
| 2 | 1613 | 1500 | 64.5 | 105 | 0.61 | 2.46 | |||||
| 3 | 2345 | 1500 | 93.8 | 105 | 0.89 | 3.57 | |||||
| 4 | 2969 | 1500 | 118.8 | 105 | 1.13 | 4.53 | |||||
| 7 | 4259 | 1500 | 170.4 | 105 | 1.62 | 6.49 | |||||
| Notes: During first week of treatment. Dosages not provided. Footnotes: a = As 2-hydroxyflutamide (the active form of flutamide). b = Assumes, on the basis of ligand binding assays, that bicalutamide possesses 4-fold greater affinity for the androgen receptor than 2-hydroxyflutamide. Sources: [1] | |||||||||||
References
edit- ^ Blackledge GR (1996). "Clinical progress with a new antiandrogen, Casodex (bicalutamide)". Eur. Urol. 29 Suppl 2: 96–104. doi:10.1159/000473847. PMID 8717470.